Fibrin is a protein formed in the human body responsible for scar tissue and thrombus formation. Neprinol contains a blend of fibrinolytic (fibrin degrading) enzymes that specifically address fibrin levels in the body. Our bodies normally secrete sufficient levels of plasmin, an important enzyme present in the blood that degrades many blood plasma proteins and blood clots. Plasmin, our own natural blood thinner, is responsible for maintaining normal blood solvency by removing unnecessary accumulated protein. The normal process of removing excessive fibrin can be enhanced by introducing fibrinolytic enzymes like those found in Neprinol.
Hyper-coagulation & Fibrin Defense
Enzymes can be thought of as proteins on a mission. And when it comes to improving your health, one of the most potent targets an enzyme can seek and destroy is a fibrous protein called fibrin. Neprinol contains a powerful combination of fibrin-dissolving enzymes like serrapeptase, nattokinase and bromelain, as well as other natural ingredients. That is why it is known as Neprinol AFD – Advanced Fibrin Defense®. But to understand why the body needs help defending itself against fibrin you first need to understand a bit more about the protein itself.
Fibrin is an insoluble protein that plays a major role in the formation of blood clots and scar tissue. During the blood clotting process, the soluble protein fibrinogen converts into insoluble fibrin, which is then laid down inside the damaged blood vessel. The fibrin strands then assemble into a net-like gel that hardens and captures all of the materials necessary to patch the damaged vessel. This is the structural framework of a blood clot. Obviously, fibrin plays a vital role in the healing process; however, when there is fibrin overproduction, it can lead to the formation of dangerous and unnecessary blood clots in the body . One factor that can lead to excessive fibrin is ageing.
As we age, the concentration of fibrinogen increases in our blood . High levels of fibrinogen increases fibrin production, and as fibrin begins to accumulate in the blood vessels it generally leads to the formation of blood clots . Healthy individuals usually have sufficient levels of plasmin, an enzyme that breaks up fibrin blood clots. Unfortunately plasmin production slows down as we get older so the normal process of removing excess fibrin is reduced. The result of this can be cardiovascular disease, heart attacks, strokes, pulmonary emboli, deep vein thrombosis (DVT) and other related disorders [4-8].
Research has shown that protein-dissolving enzymes like those found in Neprinol can slow the production of fibrin and enhance its removal from the body . Neprinol's blend of enzymes generally tests well above 50,000 FU per gram, which means that 50,000 units of fibrin are broken down by each gram of Neprinol powder. Of the enzymes contained in this formula perhaps the most significant is nattokinase, which has been shown to be four times more powerful than our body's own plasmin at breaking down blood clots .
Nattokinase is an enzyme extracted from natto, a fermented soybean 'cheese' that is popular in Japan . The ability of nattokinase to breakdown fibrin has been tested in more than 12 studies , and nattokinase has been shown to be the most potent fibrin-degrading enzyme out of more than 200 foods tested .
Researchers have found that nattokinase works much in the same way as plasmin , which means thatnattokinase literally dissolves fibrin, whether it is holding together blood clots or is part of scar tissue . However, nattokinase also blocks the activity of plasminogen activator inhibitor 1 (PAI-1), which boosts its fibrin-destroying capabilities even more [9,13].
Plasminogen is made into plasmin, the body's fibrin-dissolving enzyme. However, the conversion process is inactivated by PAI-1. This is why high levels of PAI-1 reduce fibrin breakdown and removal . Nattokinase increases fibrin breakdown by blocking PAI-1 so that more plasmin is produced.
Because of this nattokinase is not only able to stop dangerous blood clots from developing but also helps dissolve any clots that have already formed. As a result, oral nattokinase supplements are recommended for preventing cardiovascular disease . Nattokinase has also been shown to reduce the risk of deep vein thrombosis (DVT) in high-risk patients in combination with pycnogenol.
Bromelain is an extract from pineapple that contains a number of fibrin-degrading enzymes [17,18], as well as enzymes that enhance this fibrin-dissolving action . Bromelain was shown to increase the conversion of plasminogen into plasmin [20-22]. It has also been shown to prevent the conversion of fibrinogen to fibrin . However, unlike nattokinase, bromelain is not able to dissolve fibrin clumps that have already formed .
Because a high percentage of ingested bromelain is absorbed intact into the bloodstream, protein- and fibrin-degrading activity in the blood can be increased for hours after taking it . Two large-scale trials in patients with heart problems showed that bromelain could almost completely eliminate thrombosis .
Serrapeptase is another important component of Neprinol's advanced fibrin defense. Serrapeptase is a protein-degrading enzyme isolated from the silk worm . It has significant anti-inflammatory and fibrin-removal activity , which makes it ideal for preventing blood clot formation associated with cardiovascular disease.
Other Diseases Linked to Fibrin
The buildup of excess fibrin in the body can cause more health problems than just blood clots. Fibrin has also been linked to a number of chronic and progressive diseases like multiple sclerosis [27,28] and asthma . As a result, Neprinol's fibrin-degrading enzymes could prove to be a good treatment option [1,30].
Breaking down fibrin using enzymes may also help a number of conditions that are difficult to treat, such as Peyronie’s disease, Dupuytren’s contracture and Ledderhose’s disease. All of these conditions are characterized by a loss of tissue elasticity, which leads to tissue tearing, then bleeding, clot formation and fibrin deposition. Over time, taking fibrin-degrading enzymes may reduce the amount of scar tissue built up in locations where there has been repeated damage and bleeding .
Finally, using enzymes to dissolve fibrin may also play a role in cancer prevention and treatment. Cancer cells often are surrounded by a fibrin coating . Researchers think that the fibrin may provide a type of camouflage for these abnormal cells, allowing them to escape being destroyed by the immune system. It is possible that by removing this fibrin coating, the body could detect cancer cells and destroy them before they are able to gain a foothold in the body.
Advanced Fibrin Defense
As you can see, excess fibrin can wreak havoc on our bodies, especially as we get older and our natural production of enzymes decreases. However, Neprinol provides a combination of superior fibrin-active enzymes designed to keep fibrin levels in check. Neprinol is an excellent choice for anyone suffering from, or hoping to prevent, the harmful effects of excess fibrin.
Like us on Facebook and stay up to date on all specials and product giveaways.
- Meletis CD, Barker JE. Therapeutic enzymes: using the body's helpers as healers. Alt Comp Ther. 2005;74-77.
- Meade TW. Fibrinogen and cardiovascular disease. J Clin Pathol. 1997;50:13-15.
- Milner M, Makise K. Natto and its Active Ingredient Nattokinase: a potent and safe thrombolytic agent. Alt Comp Therap. 2002;8(3):157-164.
- Koenig W. Fibrin(ogen) in cardiovascular disease: an update. Thromb Haemost. 2003;89:601-609.
- Lefevre M, Kris-Etherton PM, Zhao G, Tracy RP. Dietary fatty acids, hemostasis, and cardiovascular disease risk. J Am Diet Assoc. 2004;104:410-419.
- Kannel WB. Overview of hemostatic factors involved in atherosclerotic cardiovascular disease.Lipids. 2005;40:1215-1220.
- Eidelman RS, Hennekens CH. Fibrinogen: a predictor of stroke and marker of atherosclerosis.Eur Heart J. 2003;24:499-500.
- Nesheim M. Myocardial infarction and the balance between fibrin deposition and removal. Ital Heart J. 2001;2:641-645.
- Fujita M, Hong K, Ito Y, et al. Thrombolytic effect of nattokinase on a chemically induced thrombosis model in rat. Biol Pharm Bull. 1995;18:1387-1391.
- Sumi H, Hamada H, Tsushima H, Mihara H, Muraki H. A novel fibrinolytic enzyme (nattokinase) in the vegetable cheese Natto; a typical and popular soybean food in the Japanese diet.Experientia. 1987;43:1110-1111.
- Pais E, Alexy T, Holsworth RE Jr, Meise HJ. Effects of nattokinase, a pro-fibrinolytic enzyme, on red blood cell aggregation and whole blood viscosity. Clin Hemorheol Microcirc. 2006;35:139-142.
- Sumi H, Hamada H, Nakanishi K, Hiratani H. Enhancement of the fibrinolytic activity in plasma by oral administration of nattokinase. Acta Haematol. 1990;84:139-143.
- Suzuki Y, Kondo K, Matsumoto Y, et al. Dietary supplementation of fermented soybean, natto, suppresses intimal thickening and modulates the lysis of mural thrombi after endothelial injury in rat femoral artery. Life Sci. 2003;73:1289-1298.
- Hamsten A, de Faire U, Walldius G, et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction.Lancet. 1987;2:3-9.
- Hsia C-H, Shen M-C, Lin J-S, et al. Nattokinase decreases plasma levels of fibrinogen, factor VII, and factor VIII in human subjects. Nutr Res. 2009;29:190-196.
- Cesarone MR, Belcaro G, Nicolaides AN, et al. Prevention of venous thrombosis in long-haul flights with Flite Tabs: The LONFLIT-FLITE randomized, controlled trial. Angiology. 2003;54:531-539.
- Maurer HR. Bromelain: biochemistry, pharmacology and medical use. Cell Mol Life Sci.2001;58:1234-1245.
- Pirotta F, de Giuli-Morghen C. Bromelain: antiinflammatory and serum fibrinolytic activity after oral administration in the rat. Drugs Exp Clin Res. 1978;4:1-20.
- Ako H, Cheung AH, Matsuura PK. Isolation of a fibrinolysis enzyme activator from commercial bromelain. Arch Int Pharmacodyn Ther. 1981;254(1):157-167.
- Maurer HR, Eckert K, Grabowska E, Eschmann K. Use of bromelain proteases for inhibiting blood coagulation. Patent WO PCT/EP 98/04406. 2000.
- De-Giuli M, Pirotta F. Bromelain, interaction with some protease inhibitor and rabbit specific antiserum. Drugs Exp Clin Res. 1978;4:21-23.
- Smyth RD, Brennan R, Martin GJ. Systemic biochemical changes following the oral administration of a proteolytic enzyme, bromelain. Arch Int Pharmacodyn. 1962;136:230-236.
- Taussig SJ. The mechanism of the physiological action of bromelain. Med Hypotheses. 1980;6(1):99-104.
- Felton GE. Fibrinolytic and antithrombotic action of bromelain may eliminate thrombosis in heart patients. Med Hypotheses. 1980;6(1):1123-1133.
- Sandhya KV, Devi SG, Mathew ST. Quantitation of serrapeptase in formulations by UV method in the microplate format. Curr Drug Deliv. 2008;5(4):303-305.
- Mazzone A, Catalani M, Costanzo M, et al. Evaluation of Serratia peptidase in acute or chronic inflammation of otorhinolaryngology pathology: A multicentre, doubleblind, randomized trial versus placebo. J Int Med Res. 1990;18:379-388.
- Sobel RA, Mitchell ME. Fibronectin in multiple sclerosis lesions. Am J Pathol.1989;135:161-168.
- Gveric D, Hanemaaijer R, Newcombe J, van Lent NA, Sier CF, Cuzner ML. Plasminogen activators in multiple sclerosis lesions: implications for the inflammatory response and axonal damage. Brain.2001;124(Pt 10):1978-1988.
- Pretorius E, Oberholzer HM. Ultrastructural changes of platelets and fibrin networks in human asthma: a qualitative case study. Blood Coagul Fibrinolysis. 2009;20(2):146-149.
- Akassoglou K, Adams RA, Bauer J, et al. Fibrin depletion decreases inflammation and delays the onset of demyelination in a tumor necrosis factor transgenic mouse model for multiple sclerosis. Proc Natl Acad Sci USA. 2004;101(17):6698-6703.
- Bardos H, Molnar P, Csecsei G, Adany R. Fibrin deposition in primary and metastatic human brain tumours. Blood Coagul Fibrinolysis. 1996;7:536-548.